Assessment of Schizophrenia Patients' Clinical Study Experiences
Not yet recruiting
- Conditions
- Schizophrenia
- Registration Number
- NCT05948111
- Lead Sponsor
- Power Life Sciences Inc.
- Brief Summary
The study seeks to delve into the firsthand experiences of patients diagnosed with schizophrenia who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.
The data collected from this study will help improve future outcomes for all schizophrenia patients as well as those in under-represented demographic groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Diagnosis of schizophrenia
- Considered reliable, able to understand, and willing to perform all study procedures
- Signed Written Informed Consent
Exclusion Criteria
- Currently enrolled in, have completed or have discontinued from a clinical trial involving an investigational drug
- Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
- Any serious and/or unstable pre-existing medical disorders
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of schizophrenia patients who remain in clinical trial to trial completion 12 months Number of schizophrenia patients who decide to enroll in a clinical trial 3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Power Life Sciences
🇺🇸San Francisco, California, United States